Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Current diagnosis of schizophrenia of paranoid, disorganized, or undifferentiated subtype~* Minimum PANSS total score of 70 at Screening and Baseline~* Score of at least 4 (moderate) in two or more of the five items in the positive subscale of the PANSS~* Confirmed to be experiencing an acute exacerbation of schizophrenia~* CGI-S scale score of at least 4 (moderately ill) at Baseline~* Has responded positively to an antipsychotic medication other than clozapine (Clozaril®) in a prior episode~Exclusion Criteria:~* Body mass index (BMI) \<18.5 or \>40.0 kg/m\^2~* Laboratory and/or clinical evidence of clinically significant hepatic conditions~* Known history of, or undergoing treatment for, narrow angle glaucoma~* Diagnosed with epilepsy or has had any seizure disorder beyond childhood febrile seizures~* Known serological evidence of human immunodeficiency virus (HIV) antibody~* History of neuroleptic malignant syndrome or tardive dyskinesias~* Past or current diagnosis of schizoaffective disorder, schizophrenia of residual subtype, schizophrenia of catatonic subtype, current diagnosis of schizophrenia with course specifiers continuous, single episode in partial remission, or single episode in full remission, or borderline personality disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Asenapine 2.5 mg BID (Type: EXPERIMENTAL): None
- Asenapine 5 mg BID (Type: EXPERIMENTAL): None
- Olanzapine 15 mg QD (Type: ACTIVE_COMPARATOR): None
- Placebo BID (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).